


 Cite this: *RSC Adv.*, 2021, **11**, 7511

# Aerobically stable and substitutionally labile $\alpha$ -diimine rhenium dicarbonyl complexes†

 Kevin Schindler,  Aurélien Crochet  and Fabio Zobi \*

New synthetic routes to aerobically stable and substitutionally labile  $\alpha$ -diimine rhenium(I) dicarbonyl complexes are described. The molecules are prepared in high yield from the *cis-cis-trans*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br<sub>2</sub>]<sup>−</sup> anion (**2**, where <sup>t</sup>Bu<sub>2</sub>bpy is 4,4'-di-*tert*-butyl-2,2'-bipyridine), which can be isolated from the one electron reduction of the corresponding 17-electron complex (**1**). Compound **2** is stable in the solid state, but in solution it is oxidized by molecular oxygen back to **1**. Replacement of a single bromide of **2** by  $\sigma$ -donor monodentate ligands (Ls) yields stable neutral 18-electron *cis-cis-trans*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] species. In coordinating solvents like methanol the halide is replaced giving the corresponding solvated cations. [Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] species can be further reacted with Ls to prepare stable *cis-cis-trans*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(L)<sub>2</sub>]<sup>+</sup> complexes in good yield. Ligand substitution of Re(I) complexes proceeds *via* pentacoordinate intermediates capable of Berry pseudorotation. In addition to the *cis-cis-trans*-complexes, *cis-cis-cis*- (all *cis*) isomers are also formed. In particular, *cis-cis-trans*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(L)<sub>2</sub>]<sup>+</sup> complexes establish an equilibrium with all *cis* isomers in solution. The solid state crystal structure of nearly all molecules presented could be elucidated. The molecules adopt a slightly distorted octahedral geometry. In comparison to similar *fac*-[Re(CO)<sub>3</sub>]<sup>+</sup> complexes, Re(I) dicarbonyl species are characterized by a bend (ca. 7°) of the axial ligands towards the  $\alpha$ -diimine unit. [Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br<sub>2</sub>]<sup>−</sup> and [Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] complexes may be considered as synthons for the preparation of a variety of new stable diamagnetic dicarbonyl rhenium *cis*-[Re(CO)<sub>2</sub>]<sup>+</sup> complexes, offering a convenient entry in the chemistry of the core.

 Received 20th January 2021  
 Accepted 5th February 2021

DOI: 10.1039/d1ra00514f

rsc.li/rsc-advances

## Introduction

The chemistry of metal complexes of the bidentate diimine Re(I) tricarbonyl core (*fac*-[Re<sup>I</sup>(CO)<sub>3</sub>]<sup>+</sup>) is widely investigated due to the rich photochemistry and photophysics of the molecules,<sup>1–3</sup> their potential applications as diagnostic and anticancer agents,<sup>4,5</sup> electro- and photoinduced-catalysts,<sup>6,7</sup> artificial photosynthetic<sup>8</sup> and supramolecular materials.<sup>9</sup> In comparison, the chemistry of the Re(I) dicarbonyl core (*cis*-[Re<sup>I</sup>(CO)<sub>2</sub>]<sup>+</sup>) is rare. In general the chemistry of Re(I) dicarbonyl complexes is dominated by  $\pi$ -acids ligands which effectively replace electronically the role of the “missing” carbonyl and stabilize the d<sub>6</sub> core *via*  $\pi$ -back bonding. In most cases, such species are substitutionally inert, thereby limiting our understanding of the core. To our knowledge, there are no examples of [2 + 1] complexes of *cis*-[Re<sup>I</sup>(CO)<sub>2</sub>] species (where 2 + 1 indicates the combination of a bidentate and a monodentate ligand) in which one of the two is not a  $\pi$ -acid ligand of the PR<sub>3</sub> (phosphine and phosphites), NCR or CNR (nitrile or isonitrile), CN<sup>−</sup> or NO<sup>+</sup> type.

Chemically the majority of Re(I) dicarbonyl species is prepared in one of three ways: by trimethylamine *N*-oxide (Me<sub>3</sub>NO), photolytic or thermal decarbonylation. Trimethylamine *N*-oxide (Me<sub>3</sub>NO) reacts selectively and irreversibly with metal bound CO following a second-order rate law consistent with a bimolecular mechanism.<sup>10</sup> The reagent has been used successfully for the decarbonylation of different Re tricarbonyl complexes.<sup>10–17</sup> Kurtz *et al.*, *e.g.*, prepared a series of compounds of the type *cis*-[Re(diimine)(CO)<sub>2</sub>(L)Cl] (where L = P(OEt)<sub>3</sub>, PMe<sub>3</sub>) by exploiting the *trans*-labilizing effect of phosphorus ligands to facilitate carbonyl replacement.<sup>12,17</sup> Similarly the group of Wilson synthesized and structurally characterized analogous complexes as the active photoactivated species in a study that reported the *in vitro* anticancer activity of rhenium(I) tricarbonyl complexes bearing water-soluble phosphines.<sup>13</sup>

Nitrile and isonitrile ligands (together with other  $\pi$ -acids such as PR<sub>3</sub>, *vide infra*) dominate the coordination chemistry of dicarbonyl Re(I) complexes. In the early 2000's Kromer and Alberto introduced and studied the substitution chemistry of *cis-trans*-[Re(CO)<sub>2</sub>(CH<sub>3</sub>CN)<sub>2</sub>Br<sub>2</sub>]<sup>−</sup> species.<sup>18,19</sup> The two acetonitriles are strongly bound and are not substituted by mono- and bidentate ligands. In the last decade the groups of Ko and Ishitani have introduced tunable isocyno and acetonitrile

Department of Chemistry, Fribourg University, Chemin Du Musée 9, 1700, Fribourg, Switzerland. E-mail: fabio.zobi@unifr.ch

† Electronic supplementary information (ESI) available. CCDC 2056997–2057005. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d1ra00514f








Fig. 1 Crystal structures of compound **1** (top) and the  $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{BrCl}]$  complex (**Cl-1**) obtained from the attempted crystallization of **2** in  $\text{CHCl}_3$  under inert atmosphere. Thermal ellipsoids are at 30% probability.

Multiple attempts of crystallization of **2** (inert atmosphere, glove box), or the equivalent  $\text{CoCp}_2^+$  salt, failed. We only succeeded in isolating the  $[\text{Re}^{\text{II}}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{BrCl}]$  complex (**Cl-1**) from layering pentane on a chloroform solution of **2** (Fig. 1). Even though crystals grew under inert conditions, the X-ray structure revealed the oxidized  $\text{Re}^{\text{II}}$  product. Moreover, a surprising exchange of bromide for chloride, abstracted from chloroform, was observed. We did not study this reaction further and made no attempts to elucidate its possible mechanism.

With complex **2** in our hands, we moved to explore the substitution chemistry of the species (Scheme 1, section B). Substitution reactions of one bromide ion were studied under inert conditions with  $\sigma$ -donor ligands *L*, such as pyridine (py) and *N*-methylimidazole (NMI). Reactions were initially

attempted with increasing equivalents of *L* in different solvents like methanol. However, due to low yields and back oxidation of **2** to **1**, we ultimately decided to use py and NMI as solvents for the same reactions. This procedure gave excellent results with yields for the desired  $[\text{Re}^{\text{I}}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{Br}(\text{L})]$  products (**3** for *L* = py and **t-4** with *L* = NMI, see Scheme 1) > 85%. Substitution of one  $\text{Br}^-$  ligand for py or NMI imparts aerobic stability to  $[\text{Re}^{\text{I}}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{Br}(\text{L})]$  species, both in solid state and in solution. The presence of two coordinated  $\pi$ -donor bromide ions stabilizes the 17-electron complexes. The effect is lost when a bromide is exchanged by a  $\sigma$ -donor, and the resulting 18-electron complexes are stable. Complexes  $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{Br}(\text{py})]$  (**3**) and  $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{Br}(\text{NMI})]$  (**t-4**) are stable enough to be purified *via* flash column chromatography. We found that aluminum oxide is a better stationary phase than silica for these rhenium(i) dicarbonyl species. During the purification of the complexes, we noticed a faint green-blue band eluting first on alumina (**3** and **t-4** are isolated as brick red powders). In the case of the NMI reaction we were able to isolate enough of the product and we identified it as the all *cis*- $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{Br}(\text{NMI})]$  isomers (**c-4**, see Scheme 1). This green-blue side product was also crystallized along **3** and **t-4** from layering pentane on DCM solutions of the complexes (Fig. 2 and 3). The presence of **c-4** is interesting as it suggests a dissociative type of substitution mechanism, whereby replacement of Br in **2** may proceed *via* a pentacoordinate intermediate capable of Berry pseudorotation. Reaction of **2** with a strong  $\pi$ -acid ligand such as triphenylphosphine ( $\text{PR}_3$ ) yields the equivalent  $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})\text{Br}(\text{PR}_3)]$  species (**5**) in low yield. This type of complexes are well known and other synthetic procedures (*e.g.*  $\text{Me}_3\text{NO}$  or photolytic decarbonylation of the *fac*- $[\text{Re}(\text{CO})_3]^+$  core) appear superior. The solid-state structure of **5** is also given in Fig. 2.

As mentioned above, **3** and **t-4** are aerobically stable in solution. When dissolved in methanol, HPLC-MS analysis revealed the formation of the solvated  $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})(\text{L})(\text{CH}_3\text{OH})]^+$  ion in nearly quantitative yield (**3s** and **t-4s** in Scheme 1, section C). Indeed, we found no differences in the HPLC traces of the species whether treated with  $\text{AgPF}_6$  (1.1 eq.) or not. The presence of the solvated ion clearly indicated the possibility of replacing the second coordinated Br. Therefore, we attempted the preparation of  $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})(\text{L})(\text{L}')]^+$  complexes with the same  $\sigma$ -donor ligands *L*. Addition of py or NMI to **3** or **t-4**, gives the corresponding  $[\text{Re}(\text{CO})_2(\text{t}\text{-Bu}_2\text{bpy})(\text{L})_2]^+$

Table 1 Physical properties for complexes **2**, **3**, **t-4**, **6**, **7** and **8**

Complex	$\nu(\text{CO})$ [ $\text{cm}^{-1}$ ]	Predicted $\nu(\text{CO})$ [ $\text{cm}^{-1}$ ]	$\lambda_{\text{max}}$ [ $\text{nm}$ ( $\text{M}^{-1} \text{cm}^{-1}$ )]
<b>1</b>	1993, 1853	1995	301(12 993), 426 (4753)
<b>2</b>	1864, 1774	1864	295 (20 331), 306 (14 436), 418 (3444), 567 (546)
<b>3</b>	1885, 1807	1882	298 (16 616), 306 (18 852), 384 (7188), 518 (2922)
<b>t-4</b>	1876, 1789	1872	297 (17 723), 306 (20 141), 382 (3154), 518 (2705)
<b>6</b>	1899, 1818	1900	301 (19 479), 359 (10 961), 471 (3104),
<b>7</b>	1893, 1810	1890	304 (12 397), 358 (4644), 461 (1963)
<b>8</b>	1886, 1800	1880	304 (14 826), 356 (2702), 483 (2194),






Fig. 2 Crystal structures (top to bottom) of compounds 3, t-4 and 5. Thermal ellipsoids are at 30% probability.

or  $[\text{Re}(\text{CO})_2(\text{}^t\text{Bu}_2\text{bpy})(\text{L})(\text{L}')]^+$  species in good yield (6–8, Scheme 1, section C). Complexes  $[\text{Re}(\text{CO})_2(\text{}^t\text{Bu}_2\text{bpy})(\text{py})_2](\text{PF}_6)$  (6),  $[\text{Re}(\text{CO})_2(\text{}^t\text{Bu}_2\text{bpy})(\text{py})(\text{NMI})](\text{PF}_6)$  (7) and  $[\text{Re}(\text{CO})_2(\text{}^t\text{Bu}_2\text{bpy})(\text{NMI})_2](\text{PF}_6)$  (8) were isolated as  $\text{PF}_6^-$  salts following treatment of aqueous solutions of the corresponding bromide salts with  $\text{KPF}_6$ . We note that 7 can be obtained from either reaction of 3 with NMI or t-4 with py. X-ray quality single crystals of compounds 6–8 were obtained by layering pentane on a DCM solution of the species. Their molecular structures are shown in Fig. 4. These molecules are also aerobically stable both in solid state and in solution. Complexes are soluble in DCM, acetonitrile and methanol and they are all photolytically stable.

When NMR spectra of  $[\text{Re}(\text{CO})_2(\text{}^t\text{Bu}_2\text{bpy})(\text{L})(\text{L}')]^+$  species were analyzed, we realized that all *cis* isomers also formed (Scheme 2




Fig. 3 Crystal structures of all *cis* isomers c-4. Thermal ellipsoids are at 30% probability.

and Fig. 5). As it is the case for the first substitution reaction of 2, further ligand replacement of  $[\text{Re}(\text{CO})_2(\text{}^t\text{Bu}_2\text{bpy})\text{Br}(\text{L})]$  complexes occurs according to a dissociative type of substitution mechanism proceeding *via* a pentacoordinate intermediate capable of Berry pseudorotation. Attempts to isolate the major *trans* stereoisomers in pure form (6–8, Scheme 1, section C) did not succeed. Although the *trans* and all *cis* isomers are well separated on alumina (ethyl acetate/pentane mobile phase) NMR spectra of purified 6–8 still revealed the presence of the other geometrical isomers, pointing to a rapid equilibrium of the species in solution. Similar results were obtained when single crystals of 6–8 were analyzed by the technique. *Trans* and *cis* isomers ratios were determined to be respectively 70.9–29.1% after purification and 79.5–20.5% from crystals for 6; 85.5–14.5% and 85.6–15.4% for 7; 86.6–13.4% and 88.9–11.1% for 8. The relative *cis* enantiomers ratio was closely distributed as 1 : 1 for all complexes.

### X-ray crystallography

Crystallographic details, selected bond lengths and angles of complexes 1–8 (Fig. 1–4), are reported in ESI. As mentioned in the introduction, *cis*- $[\text{Re}(\text{CO})_2]^+$  complexes lacking at least a  $\pi$ -acid ligands are not known. Structural analysis of the species and comparison to related *fac*- $[\text{Re}(\text{CO})_3]^+$  species, revealed some interesting characteristics. All *cis*- $[\text{Re}(\text{CO})_2]^+$  complexes show a distorted octahedral geometry around the Re ion. Perhaps the most striking feature is represented by the bending (*ca.* 7°) of







Fig. 4 Crystal structures (top to bottom) of compounds 6, 7 and 8. Thermal ellipsoids are at 30% probability.

the *trans* axial ligands ( $^t$ Ls) towards the  $\alpha$ -diimine ligand (Scheme 3). In  $[\text{Re}(\text{CO})_2(\text{Bu}_2\text{bpy})(\text{L})_2]^n$  complexes, the angle formed by the  $^t\text{L}-\text{Re}-^t\text{L}$  unit is on average  $172^\circ$ , with **t-4** showing the lowest value ( $169.38(10)^\circ$ ). The  $^t\text{L}-\text{Re}-^t\text{L}$  angle is significantly smaller than the corresponding *fac*- $[\text{Re}(\text{CO})_3]^+$  analogs (on average by *ca.*  $7^\circ$ ). A conquest search of the CCDC indicates that other crystallographic parameters around the rhenium ion in *cis*- $[\text{Re}(\text{CO})_2]^+$  species (bond lengths and angles) are not



Scheme 2 Major stereoisomers formed in the reaction of  $[\text{Re}(\text{CO})_2(\text{Bu}_2\text{bpy})\text{Br}(\text{L})]$  complexes with a second ligand L, and most probable substitution mechanism.





Fig. 5 Aromatic region of  $^1\text{H}$ -NMR spectra of purified complexes 6 and 8. Asterisks indicate signals of all *cis* isomers formed in solution.



Scheme 3 Main structural differences between related diimine *cis*- $[\text{Re}(\text{CO})_2]^+$  and *fac*- $[\text{Re}(\text{CO})_3]^+$  species.

significantly dissimilar than the ones reported for comparable *fac*- $[\text{Re}(\text{CO})_3(\alpha\text{-diimine})(\text{L})]^+$  species ( $\text{L} = \text{py}$  or  $\text{NMI}$ ).

### Spectroscopic characterization

Physical properties of *cis*- $[\text{Re}(\text{CO})_2]^+$  complexes are summarized in Table 1. The IR spectra of the compounds show the typical pattern expected for the dicarbonyl moiety with *cis* geometry, with bands in the range of  $1900$  to  $1800\text{ cm}^{-1}$  (Fig. 6). As expected, the carbonyl stretching frequencies are significantly lower than the corresponding *fac*- $[\text{Re}(\text{CO})_3]^+$  tricarbonyl species. The comparison of the symmetric  $\text{C}\equiv\text{O}$  stretching vibration






Fig. 6 IR spectra of 1, 2, 3, 6 (top). Measured versus predicted symmetric stretching vibration of CO bond for complex 2, 3, t-4, 6, 7, 8 (bottom).

frequencies between complexes can be correlated to the electron donating ability of each ligand bound to the metal center. Thus, *e.g.*, the stepwise substitution of the  $\pi$ -donor halide with the  $\sigma$ -donor py induced a stepwise hypsochromic shift of the CO stretching vibration (*ca.*  $15\text{ cm}^{-1}$ , see Fig. 6) due to decrease  $\pi$ -backbonding from the rhenium ion. Previously, we have shown that the symmetric CO stretching vibration frequency can be predicted by empirical calculations based on individual ligand contribution.<sup>56–58</sup> This method provides precise estimates of frequencies for the *cis*-[Re(CO)<sub>2</sub>]<sup>+</sup> cores, among others. This assessment is established by the formula

$$\nu_{\text{CO}} = S_{\text{R}}[\sum IR_{\text{p}}(L)] + I_{\text{R}}$$

with  $S_{\text{R}} = 2.00$  and  $I_{\text{R}} = -2115.6$ . The  $\sum [IR_{\text{p}}(L)]$  term is the sum of the contribution for each ligand to the frequency.  $S_{\text{R}}$  and  $I_{\text{R}}$  are constants, which depend on the metal center, its oxidation state and the number of coordinated CO. The measured frequencies are in good agreement with values predicted from this empirical parametrization (Fig. 6).

The UV-Vis spectra of the compounds are generally characterized by three main absorptions. All complexes show similar  $\pi \rightarrow \pi^*$  intra-ligand transitions (LLCT) as sharp bands in the 300 nm region attributed to the diimine-ligand system. In addition, the spectra show two lower lying less intense

absorption in the 350–400 and 460–520 nm regions respectively. We initially hypothesized that the latter could be attributed to metal-to-ligand charge transfer transitions (MLCT), but TDDFT and orbital analysis revealed that these absorptions can at best be described as metal-ligand-to-ligand charge transfer transitions (MLLCT) of substantial (>60%) ligand character. These MLLCTs involve frontier, HOMO–1 and LUMO+1 orbital transitions. In the case of 2 and the [Re<sup>I</sup>(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] or [Re<sup>I</sup>(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(L)<sub>2</sub>]<sup>+</sup> species (where L = NMI, *i.e.* t-4, c-4 and 8, see ESI<sup>†</sup>) the absorptions are well separated and show similar extinction coefficients. In complexes where L = py, the MLLCT in the 350–400 nm region is more intense and the two absorptions are not as well-separated (Fig. 7).

In relative terms, substitution of the halide by L in [Re<sup>I</sup>(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] complexes, induces an hypsochromic shift of both MLLCT maxima, which are centered respectively around 380 and 520 nm in [Re<sup>I</sup>(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] species and 360 and 470 nm in [Re<sup>I</sup>(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(L)<sub>2</sub>]<sup>+</sup> cations (Table 1). With the exception of NMI complexes, the shift is mainly attributed to the destabilization of LUMO orbitals energies (see ESI<sup>†</sup>). With the exception of 5, in contrast to *fac*-[Re<sup>I</sup>(CO)<sub>3</sub>]<sup>+</sup>




Fig. 7 Measured (red) and calculated (blue) UV-Vis spectra (all in DMF) of selected complexes (3, 6 and 7) together with calculated oscillator strength (black). The HOMO and LUMO of each corresponding molecule are shown to the right of the graphs.



complexes, the significant ligand character of the MLLTCs of *cis*-[Re<sup>I</sup>(CO)<sub>2</sub>]<sup>+</sup> species renders the same nonemissive, and none of the complexes show photoluminescent properties.

## Conclusions

We prepared and investigated a new series of stable rhenium(I) dicarbonyl species, obtained from the *cis-cis-trans*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br<sub>2</sub>]<sup>-</sup> anion (**2**) by the reduction of the corresponding rhenium(II) complex (**1**). Substitution of a single bromide in **2** by monodentate ligands yielded 18-electron *cis-cis-trans*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] compounds. The second bromide could be easily substituted in coordinating solvents, such as methanol and then replaced by a second  $\sigma$ -donor monodentate ligand giving *cis-cis-trans*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(L)<sub>2</sub>]<sup>+</sup> cations. We observed the formation of *cis-cis-cis*-[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(L)<sub>2</sub>]<sup>+</sup> isomers, induced by a Berry pseudorotation involved in the ligand substitution mechanism. Crystallography analysis showed a slightly distorted octahedral geometry for all species, in which *trans* axial monodentate ligands are bent (*ca.* 7°) towards the  $\alpha$ -diimine. In the IR spectrum, these complexes are characterized by a typical pattern expected for the dicarbonyl moiety with *cis* geometry, with bands in the range of 1900 to 1800 cm<sup>-1</sup>. Symmetric stretching vibration of CO bond were analyzed and compared with empirical calculations, showing a good correlation with predictive theoretical models. TDDFT calculations allowed assignment of UV-Vis electronic transitions and orbitals involved in the same. The complexes are characterized by metal-ligand-to-ligand charge transfer transitions (MLLCT) of substantial ligand character. [Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br<sub>2</sub>]<sup>-</sup> and [Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(L)] complexes may be considered as synthons for the preparation of a variety of new stable diamagnetic dicarbonyl rhenium *cis*-[Re(CO)<sub>2</sub>]<sup>+</sup> complexes, offering a convenient entry in the chemistry of the core.

## Experimental section

### Reagents and chemicals

All reagent and solvents were purchased from standard sources and used without further purification. Complexes [Re(CO)<sub>5</sub>Br]<sub>2</sub><sup>59</sup> (Et<sub>4</sub>N)<sub>2</sub>[Re(CO)<sub>3</sub>Br<sub>3</sub>]<sup>60</sup> and (Et<sub>4</sub>N)[Re(CO)<sub>2</sub>Br<sub>4</sub>]<sup>61</sup> were synthesized according to published procedures. Unless otherwise noted, solvents used in the preparation of all molecules were dry and O<sub>2</sub>-free.

### Instruments and analysis

NMR spectra were measured on a Bruker Advance III 500 or 400 MHz. The corresponding <sup>1</sup>H chemical shifts are reported relative to residual solvent protons. Mass analyses were performed either using ESI-MS on a Bruker FTMS 4.7-T Apex II in positive mode or MALDI with a Bruker UltrafleXtreme MALDI-TOF. UV-Vis spectra were measured on a Jasco V730 spectrophotometer. IR spectra were recorded on a Bruker TENSOR II with the following parameters: 16 scans for background, 32 scans for sample with a resolution of 4 cm<sup>-1</sup> in the 4000 to 600 cm<sup>-1</sup>

region. Analytical HPLCs were performed with a Merck Hitachi L-7000 system, which comprises a pump L-7100 and a UV-detector L-7400. For preparative HPLC, a column Macherey-Nagel Nucleodur C18 HTec (5  $\mu$ m particle size, 110 Å pore size, 250 × 21 mm) was used. Aqueous trifluoroacetic acid 0.1% solution (A) and pure methanol (B) were respectively used as solvents. The compounds were analyzed using the following gradient: 0–5 min (75% A), 5–35 (75% A → 0% A), 35–45 min (100% B) or 0–5 min (50% A), 5–30 (50% A → 0% A), 30–45 min (100% B), the flow rate set to 5 mL min<sup>-1</sup> and the compounds detected at 260 nm. Single crystal diffraction data collection was performed on a Stoe IPDS2 diffractometer (CuK $\alpha$ 1 ( $\lambda$  = 1.5406 Å)) equipped with a cryostat from Oxford Cryosystems. The structure were solved with the ShelXT structure solution program using Intrinsic Phasing and refined with the ShelXL refinement package using Least Squares minimisation. All crystal structures are deposited at the Cambridge Crystallographic Data Centre. CCDC numbers 2056997–2057005 contain the supplementary crystallographic data for this paper.

### DFT and TDDFT calculations

All computations were performed with the Gaussian 09 programs. Geometry optimizations as well as frequency calculations were performed in the gas phase. The hybrid *meta*-GGA functional wB97XD,<sup>62–66</sup> designed to account for dispersion, was used in combination with the standard SDD basis sets.<sup>67</sup> For the spin state of the complexes (singlet state in all cases expect **1**), the default spin formalism was followed in the calculations and default Gaussian 09 values were adopted for the numerical integration grids, self-consistent-field (SCF) and geometry optimization convergence criteria. Geometries were optimized without symmetry restrictions. The nature of the stationary points was checked by computing vibrational frequencies in order to verify true minima. No imaginary frequencies were observed for the reported values. Electronic transition energies and oscillator strengths were then calculated at their wB97XD-optimized geometries using TDDFT. For these calculations the 40 lowest energy electronic excitations were calculated for each compound, and solvent effects were added *via* a solvent continuum dielectric model using DMF as the solvent. The calculated molecular orbitals were visualized using GaussView.

### Synthetic procedures

[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br<sub>2</sub>] (**1**). Complex (Et<sub>4</sub>N)[Re(CO)<sub>2</sub>Br<sub>4</sub>] (20 mg, 0.029 mmol) and 4,4'-di-*tert*-butyl-2,2'-bipyridine (8 mg, 0.029 mmol) were dissolved in DCM (7 mL). The mixture was stirred at room temperature for 3 h. The solvent was evaporated, and the product was purified on silica by flash column chromatography (eluent : EtOAc/pentane 1 : 8). Compound **1** was isolated as a red solid. Yield: 13 mg, 0.019 mmol, 67%. Single crystals suitable for X-ray diffraction were grown by layering pentane on a CH<sub>2</sub>Cl<sub>2</sub> solution of the compound giving dark-red crystals. IR (cm<sup>-1</sup>),  $\nu_{\text{CO}}$ : 1993, 1853. UV-Vis (DMF),  $\lambda_{\text{max}}$  ( $\epsilon$ ) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 426 (4753), 301 (12 993). NMR: not available because of paramagnetic compound. ESI-MS (MeOH): *m/z*, 693.7 [M + Na]<sup>+</sup>.



(TDAE)[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br<sub>2</sub>]<sub>2</sub> (2). Complex 1 (58 mg, 0.086 mmol) was dissolved in DCM (20 mL) in a schlenk flask in the glove box. TDAE (10 μL, 0.043 mmol, 0.5 eq.) was dissolved in DCM (1 mL) and slowly added to the stirring solution of 1. A dark powder began to precipitate immediately. The mixture was stirred for 15 min, and then carefully filtered to collect a purple solid, which was then dried *in vacuo*. Yield: 62 mg, 0.04 mmol, 94%. IR (cm<sup>-1</sup>), ν<sub>CO</sub>: 1864, 1774. UV-Vis (DMF), λ<sub>max</sub> (ε) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 567 (546), 418 (3444), 306 (14 436), 295 (20 331). <sup>1</sup>H-NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 8.56 (d, *J* = 0.61, 5.26 Hz, 2H, H4 (bpy)), 8.44 (d, 2H, H1 (bpy)), 7.32 (dd, *J* = 1.96, 5.14 Hz, 2H, H2 (bpy)), 2.95 (s, 2H, H(TDAE)), 2.93 (s, 2H, H(TDAE)), 2.76 (s, 8H, H(TDAE)), 1.38 (s, 18H, H7 (bpy)). <sup>13</sup>C-NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 161.44 (2C, C3 (bpy)), 156.93 (2C, C5 (bpy)), 149.50 (2C, C1 (bpy)), 121.28 (2C, C4 (bpy)), 118.50 (2C, C2 (bpy)), 38.93 (2C, C(TDAE)), 35.41 (2C, C6 (bpy)), 30.91 (6C, C7 (bpy)). ESI-MS (MeOH): *m/z*, 670.6 [M]<sup>+</sup>.

[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(py)] (3). To a solid sample of complex 2 (51 mg, 0.0332 mmol), degassed in a flask, anhydrous pyridine (5 mL, excess) was added. The suspension was heated to 100 °C for 60 min. The solvent was then evaporated and the black residue was washed with water to remove the TDAEBr<sub>2</sub>. The product was purified on aluminum oxide by flash column chromatography (eluent: EtOAc/pentane 1 : 1, increased to 2 : 1). Compound 3 was isolated as a brown solid. Yield: 38.2 mg, 0.0570 mmol, 85%. Single crystals suitable for X-ray diffraction were grown by layering pentane on a CDCl<sub>3</sub> solution of the compound giving dark-orange crystals. IR (cm<sup>-1</sup>), ν<sub>CO</sub>: 1885, 1807. UV-Vis (DMF), λ<sub>max</sub> (ε) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 518 (2922), 384 (7188), 306 (18 852), 298 (16 616). <sup>1</sup>H-NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 9.10 (d, *J* = 5.87 Hz, 2H, H4 (bpy)), 8.46 (d, 2H, H8 (py)), 8.10 (d, *J* = 1.83 Hz, 2H, H1 (bpy)), 7.52 (dd, *J* = 1.96, 5.87 Hz, 2H, H2 (bpy)), 7.48 (t, *J* = 7.64 Hz, 1H, H10 (py)), 6.92 (t, 2H, H9 (py)), 1.43 (s, 18H, H7 (bpy)). <sup>13</sup>C-NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 163.59 (2C, C3 (bpy)), 156.73 (2C, C5 (bpy)), 155.97 (2C, C8 (py)), 152.42 (2C, C1 (bpy)), 135.62 (1C, C10 (py)), 125.68 (2C, C9 (py)), 124.98 (2C, C4 (bpy)), 120.21 (2C, C2 (bpy)), 35.97 (2C, C6 (bpy)), 30.67 (6C, C7 (bpy)). ESI-MS (MeOH), *m/z*: 691.8 [M + Na]<sup>+</sup>.

[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(NMI)] (t-4). To a solid sample of complex 2 (104 mg, 0.0675 mmol), degassed in a flask, anhydrous *N*-methylimidazole (5 mL, excess) was added. The suspension was heated to 110 °C for 60 min. The solvent was then evaporated and the black residue was washed with water to remove the TDAEBr<sub>2</sub>. The product was purified on aluminum oxide by flash column chromatography (eluent: EtOAc/pentane 1 : 1, increased to 3 : 1). The first fraction was dried as a green solid, complex c-4. Yield: 2 mg, 0.00297 mmol, 2%. Compound t-4 was isolated from the second fraction as a brown solid. Yield: 77.6 mg, 0.1154 mmol, 86%. Single crystals suitable for X-ray diffraction were grown by layering pentane on a CDCl<sub>3</sub> solution of t-4 giving dark-violet crystals. IR (cm<sup>-1</sup>), ν<sub>CO</sub>: 1876, 1789. UV-Vis (DMF), λ<sub>max</sub> (ε) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 518 (2705), 382 (3154), 306 (20 141), 297 (17 723). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm) δ: 9.01 (d, *J* = 5.50 Hz, 2H, H4 (bpy)), 8.08 (s, 2H, H1 (bpy)), 7.47 (dd, *J* = 1.83, 5.75 Hz, 2H, H2 (bpy)), 7.30 (broadened, 1H, H8

(NMI)), 6.56 (s, 1H, H10 (NMI)), 6.38 (s, 1H, H9 (NMI)), 3.60 (s, 3H, H11 (NMI)), 1.43 (s, 18H, H7 (bpy)). <sup>13</sup>C-NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 163.67 (2C, C3 (bpy)), 156.99 (2C, C5 (bpy)), 152.62 (2C, C1 (bpy)), 124.37 (2C, C4 (bpy)), 121.57 (2C, C2 (bpy)), 119.64 (1C, C9 (NMI)), 35.83 (2C, C6 (bpy)), 34.43 (1C, C11 (NMI)), 30.79 (6C, C7 (bpy)). ESI-MS (MeOH): *m/z*, 694.8 [M + Na]<sup>+</sup>.

[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)Br(PPh<sub>3</sub>)] (5). To a solid sample of complex 2 (15 mg, 0.0194 mmol in Re) and triphenylphosphine (52 mg, 0.194 mmol, 10 eq.), degassed in a flask, anhydrous DME (11 mL) was added. The mixture was stirred at reflux (80 °C) during 1 h. The solvent was then evaporated and the black solid was washed with H<sub>2</sub>O to remove TDAE. The product was purified on silica by flash column chromatography (eluent: EtOAc/pentane 1 : 4, increased to 1 : 1). Compound 5 was isolated as a red solid. Yield: 2 mg, 0.0023, 12%. Single crystals suitable for X-ray diffraction were grown by layering pentane on a CH<sub>2</sub>Cl<sub>2</sub> solution of the compound giving dark-red crystals. IR (cm<sup>-1</sup>), ν<sub>CO</sub>: 1917, 1839. UV-Vis (DMF), λ<sub>max</sub> (ε) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 447, 303. <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 8.33 (d, *J* = 5.87 Hz, 2H, H4 (bpy)), 7.93 (s, 2H, H1 (bpy)), 7.21 (m, 15H, H(PPh<sub>3</sub>)), 7.04 (m, 2H, H2 (bpy)), 1.37 (d, *J* = 0.98 Hz, 18H, H7 (bpy)). ESI-MS (MeOH): *m/z*, 874.9 [M + Na]<sup>+</sup>.

[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(py)<sub>2</sub>](PF<sub>6</sub>) (6). Complex 3 (38 mg, 0.0570 mmol) was dissolved in MeOH (8 mL) and pyridine (0.5 mL). The solution was heated to 75 °C overnight. The solvent was evaporated and the solid was dissolved in water, then filtered to remove possible impurities. KPF<sub>6</sub> (15 mg, 0.0855 mmol, 1.5 eq.) dissolved in water was added and the precipitate was centrifuged. Compound 6 was filtered as a red solid. Yield: 27.3 mg, 0.0335 mmol, 59%. Single crystals suitable for X-ray diffraction were grown by layering pentane on a CH<sub>2</sub>Cl<sub>2</sub> solution of the compound giving brown crystals. IR (cm<sup>-1</sup>), ν<sub>CO</sub>: 1899, 1818. UV-Vis (DMF), λ<sub>max</sub> (ε) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 471 (3104), 359 (10 961), 301 (19 479). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm) δ: 9.20 (d, *J* = 5.87 Hz, 2H, H4 (bpy)), 8.40 (m, 4H, H8 (py)), 8.11 (d, *J* = 1.83 Hz, 2H, H1 (bpy)), 7.71 (dd, 2H, H2 (bpy)), 7.62 (tt, 2H, H10 (py)), 7.08 (m, 4H, H9 (py)), 1.43 (s, 18H, H7 (bpy)). <sup>13</sup>C-NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 206.33 (2C, C (CO)), 166.20 (2C, C3 (bpy)), 157.08 (2C, C5 (bpy)), 155.70 (4C, C8 (py)), 152.49 (2C, C1 (bpy)), 137.66 (2C, C10 (py)), 127.58 (4C, C9 (py)), 126.65 (2C, C4 (bpy)), 121.73 (2C, C2 (bpy)), 36.63 (2C, C6 (bpy)), 30.72 (6C, C7 (bpy)). ESI-MS (MeOH): *m/z*, 668.9 [M]<sup>+</sup>.

[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(py)(NMI)](PF<sub>6</sub>) (7). Complex 3 (11 mg, 0.0164 mmol) was dissolved in MeOH (7 mL) and *N*-methylimidazole (1 mL). The solution was heated to 80 °C for 3 h and 60 °C overnight. The solvent was evaporated and the solid was dissolved in water, then filtered to remove possible impurities. KPF<sub>6</sub> dissolved in water was added and the precipitate was centrifuged. Compound 7 was isolated as a red solid. Yield: 10 mg, 0.0122 mmol, 75%. Single crystals suitable for X-ray diffraction were grown by layering pentane on a CH<sub>2</sub>Cl<sub>2</sub> solution of the compound giving dark-orange crystals. IR (cm<sup>-1</sup>), ν<sub>CO</sub>: 1893, 1810. UV-Vis (DMF), λ<sub>max</sub> (ε) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 461 (1963), 358 (4644), 304 (12 397). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm) δ: 9.15 (d, *J* = 5.87 Hz, 2H, H4 (bpy)), 8.43 (d, *J* = 1.47 Hz, 2H, H8 (py)), 8.13 (d, *J* = 1.71 Hz, 2H, H1 (bpy)), 7.64 (dd, *J* =



1.96, 5.87 Hz, 2H, H2 (bpy)), 7.59 (m, 1H, H10 (py)), 7.30 (s, 1H, H11 (NMI)), 7.04 (t, 2H, H9 (py)), 6.67 (s, 1H, H13 (NMI)), 6.44 (s, 1H, H12 (NMI)), 3.54 (s, 3H, H14 (NMI)), 1.43 (s, 18H, H7 (bpy)). <sup>13</sup>C-NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 206.88 (2C, C(CO)), 165.55 (2C, C3 (bpy)), 156.57 (2C, C5 (bpy)), 155.36 (2C, C8 (py)), 152.25 (2C, C1 (bpy)), 141.51 (1C, C11 (NMI)), 136.90 (1C, C10 (py)), 132.06 (1C, C13 (NMI)), 126.21 (2C, C9 (py)), 126.14 (2C, C4 (bpy)), 122.37 (2C, C2 (bpy)), 121.20 (1C, C12 (NMI)), 36.29 (2C, C6 (bpy)), 34.78 (1C, C14 (NMI)), 30.49 (6C, C7 (bpy)). ESI-MS (MeOH): *m/z*, 671.9 [M]<sup>+</sup>.

[Re(CO)<sub>2</sub>(<sup>t</sup>Bu<sub>2</sub>bpy)(NMI)<sub>2</sub>](PF<sub>6</sub>) (**8**). Complex **t-4** (15 mg, 0.0223 mmol) was suspended in MeOH (6 mL) and *N*-methylimidazole (0.5 mL). The solution was heated to 80 °C for 2 h and 60 °C overnight, the solvent was then evaporated. The solid was dissolved in water, presolved KPF<sub>6</sub> was added. The solution was stirred for 10 minutes and then centrifugated. Compound **8** was isolated as a red solid. Yield: 7 mg, 0.00854 mmol, 38%. Single crystals suitable for X-ray diffraction were grown by layering pentane on a CH<sub>2</sub>Cl<sub>2</sub> solution of the compound giving brown crystals. IR (cm<sup>-1</sup>), ν<sub>CO</sub>: 1886, 1800. UV-Vis (DMF), λ<sub>max</sub> (ε) [nm (M<sup>-1</sup> cm<sup>-1</sup>): 483 (2194), 356 (2702), 304 (14 826). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm) δ: 9.10 (d, *J* = 5.87 Hz, 2H, H4 (bpy)), 8.14 (d, *J* = 1.71 Hz, 2H, H1 (bpy)), 7.58 (dd, *J* = 1.96, 5.87 Hz, 2H, H2 (bpy)), 7.33 (s, 2H, H8 (NMI)), 6.66 (m, 2H, H10 (NMI)), 6.43 (t, *J* = 1.41 Hz, 2H, H9 (NMI)), 3.54 (s, 6H, H11 (NMI)), 1.44 (s, 18H, H7 (bpy)). <sup>13</sup>C-NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>, ppm), δ: 207.73 (2C, C(CO)), 165.17 (2C, C3 (bpy)), 156.62 (2C, C5 (bpy)), 152.26 (2C, C1 (bpy)), 141.46 (2C, C8 (NMI)), 131.95 (2C, C10 (NMI)), 125.78 (2C, C4 (bpy)), 122.16 (2C, C2 (bpy)), 120.96 (2C, C9 (NMI)), 36.23 (2C, C6 (bpy)), 34.72 (2C, C11 (NMI)), 30.53 (6C, C7 (bpy)). ESI-MS (MeOH): *m/z*, 674.9 [M]<sup>+</sup>.

## Author contributions

K. S. investigation, formal analysis, data curation, methodology, writing – original draft; A. C. crystallography; F. Z. conceptualization, supervision, validation, writing – review & editing, funding acquisition, resources, project administration.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Financial support from the Swiss National Science Foundation (Project# 200021\_196967) is gratefully acknowledged.

## Notes and references

- 1 A. J. Lees and S. S. Sun, in *CCC II*, ed. J. A. McCleverty and T. J. Meyer, Pergamon, Oxford, 2003, pp. 731–742, DOI: 10.1016/B0-08-043748-6/01077-X.
- 2 S. Sato and O. Ishitani, *Coord. Chem. Rev.*, 2015, **282–283**, 50–59.
- 3 D. J. Stufkens, *Comments Inorg. Chem.*, 1992, **13**, 359–385.
- 4 A. Leonidova and G. Gasser, *ACS Chem. Biol.*, 2014, **9**, 2180–2193.
- 5 E. B. Bauer, A. A. Haase, R. M. Reich, D. C. Crans and F. E. Kühn, *Coord. Chem. Rev.*, 2019, **393**, 79–117.
- 6 G. F. Manbeck, J. T. Muckerman, D. J. Szalda, Y. Himeda and E. Fujita, *J. Phys. Chem. B*, 2015, **119**, 7457–7466.
- 7 J. Agarwal, E. Fujita, H. F. Schaefer and J. T. Muckerman, *J. Am. Chem. Soc.*, 2012, **134**, 5180–5186.
- 8 K. Oppelt, R. Fernández-Terán, R. Pfister and P. Hamm, *J. Phys. Chem. C*, 2019, **123**, 19952–19961.
- 9 D. L. Reger, K. J. Brown and M. D. Smith, *J. Organomet. Chem.*, 2002, **658**, 50–61.
- 10 I. M. Lorkovic, M. S. Wrighton and W. M. Davis, *J. Am. Chem. Soc.*, 1994, **116**, 6220–6228.
- 11 W. L. Ingham and N. J. Coville, *Organometallics*, 1992, **11**, 2551–2558.
- 12 D. A. Kurtz, B. Dhakal, E. S. Donovan, G. S. Nichol and G. A. N. Felton, *Inorg. Chem. Commun.*, 2015, **59**, 80–83.
- 13 S. C. Marker, S. N. MacMillan, W. R. Zipfel, Z. Li, P. C. Ford and J. J. Wilson, *Inorg. Chem.*, 2018, **57**, 1311–1331.
- 14 O. Kaufhold, A. Stasch, T. Pape, A. Hepp, P. G. Edwards, P. D. Newman and F. E. Hahn, *J. Am. Chem. Soc.*, 2009, **131**, 306–317.
- 15 S. Du, J. A. Kautz, T. D. McGrath and F. G. A. Stone, *Dalton Trans.*, 2005, 3672–3680, DOI: 10.1039/B510026G.
- 16 M. S. Jana, A. K. Pramanik, D. Sarkar, S. Biswas and T. K. Mondal, *J. Mol. Struct.*, 2013, **1047**, 73–79.
- 17 D. A. Kurtz, K. R. Brereton, K. P. Ruoff, H. M. Tang, G. A. N. Felton, A. J. M. Miller and J. L. Dempsey, *Inorg. Chem.*, 2018, **57**, 5389–5399.
- 18 L. Kromer, B. Spingler and R. Alberto, *J. Organomet. Chem.*, 2007, **692**, 1372–1376.
- 19 L. Kromer, B. Spingler and R. Alberto, *Dalton Trans.*, 2008, 5800–5806, DOI: 10.1039/B805410J.
- 20 C.-C. Ko, L. T.-L. Lo, C.-O. Ng and S.-M. Yiu, *Chem. - Eur. J.*, 2010, **16**, 13773–13782.
- 21 A. W.-Y. Cheung, L. T.-L. Lo, C.-C. Ko and S.-M. Yiu, *Inorg. Chem.*, 2011, **50**, 4798–4810.
- 22 S. Sato, A. Sekine, Y. Ohashi, O. Ishitani, A. M. Blanco-Rodríguez, A. Vlček, T. Unno and K. Koike, *Inorg. Chem.*, 2007, **46**, 3531–3540.
- 23 Y. Xiao, A. W.-Y. Cheung, S.-W. Lai, S.-C. Cheng, S.-M. Yiu, C.-F. Leung and C.-C. Ko, *Inorg. Chem.*, 2019, **58**, 6696–6705.
- 24 C.-O. Ng, S.-C. Cheng, W.-K. Chu, K.-M. Tang, S.-M. Yiu and C.-C. Ko, *Inorg. Chem.*, 2016, **55**, 7969–7979.
- 25 W.-K. Chu, X.-G. Wei, S.-M. Yiu, C.-C. Ko and K.-C. Lau, *Chem. - Eur. J.*, 2015, **21**, 2603–2612.
- 26 E. Kottelat, V. Chabert, A. Crochet, K. M. Fromm and F. Zobi, *Eur. J. Inorg. Chem.*, 2015, 5628–5638, DOI: 10.1002/ejic.201500756.
- 27 C. Triantis, A. Shegani, C. Kiritsis, M. Ischyropoulou, I. Roupa, V. Psycharis, C. Raptopoulou, P. Kyprianidou, M. Pelecanou, I. Pirmettis and M. S. Papadopoulos, *Inorg. Chem.*, 2018, **57**, 8354–8363.
- 28 J. V. Caspar, B. P. Sullivan and T. J. Meyer, *Inorg. Chem.*, 1984, **23**, 2104–2109.



- 29 E. Schutte, J. B. Helms, S. M. Woessner, J. Bowen and B. P. Sullivan, *Inorg. Chem.*, 1998, **37**, 2618–2619.
- 30 A. S. DelNegro, S. M. Woessner, B. P. Sullivan, D. M. Dattelbaum and J. R. Schoonover, *Inorg. Chem.*, 2001, **40**, 5056–5057.
- 31 O. Ishitani, K. Kanai, Y. Yamada and K. Sakamoto, *Chem. Commun.*, 2001, 1514–1515, DOI: 10.1039/B104220N.
- 32 H. Tsubaki, A. Sekine, Y. Ohashi, K. Koike, H. Takeda and O. Ishitani, *J. Am. Chem. Soc.*, 2005, **127**, 15544–15555.
- 33 Y. Yamamoto, S. Sawa, Y. Funada, T. Morimoto, M. Falkenström, H. Miyasaka, S. Shishido, T. Ozeki, K. Koike and O. Ishitani, *J. Am. Chem. Soc.*, 2008, **130**, 14659–14674.
- 34 Y. Yamamoto, Y. Tamaki, T. Yui, K. Koike and O. Ishitani, *J. Am. Chem. Soc.*, 2010, **132**, 11743–11752.
- 35 T. Morimoto, M. Ito, K. Koike, T. Kojima, T. Ozeki and O. Ishitani, *Chem. - Eur. J.*, 2012, **18**, 3292–3304.
- 36 T. Morimoto, C. Nishiura, M. Tanaka, J. Rohacova, Y. Nakagawa, Y. Funada, K. Koike, Y. Yamamoto, S. Shishido, T. Kojima, T. Saeki, T. Ozeki and O. Ishitani, *J. Am. Chem. Soc.*, 2013, **135**, 13266–13269.
- 37 T. Asatani, Y. Nakagawa, Y. Funada, S. Sawa, H. Takeda, T. Morimoto, K. Koike and O. Ishitani, *Inorg. Chem.*, 2014, **53**, 7170–7180.
- 38 J. Rohacova, A. Sekine, T. Kawano, S. Tamari and O. Ishitani, *Inorg. Chem.*, 2015, **54**, 8769–8777.
- 39 T. Morimoto and O. Ishitani, *Acc. Chem. Res.*, 2017, **50**, 2673–2683.
- 40 Y. Yamazaki, J. Rohacova, H. Ohtsu, M. Kawano and O. Ishitani, *Inorg. Chem.*, 2018, **57**, 15158–15171.
- 41 Y. Yamazaki and O. Ishitani, *Inorg. Chem.*, 2019, **58**, 12905–12910.
- 42 C.-O. Ng, S.-M. Yiu and C.-C. Ko, *Inorg. Chem.*, 2014, **53**, 3022–3031.
- 43 S. E. Kabir, J. Alam, S. Ghosh, K. Kundu, G. Hogarth, D. A. Tocher, G. M. G. Hossain and H. W. Roesky, *Dalton Trans.*, 2009, 4458–4467, DOI: 10.1039/B815337J.
- 44 B. Laramée-Milette, F. Nastasi, F. Puntoriero, S. Campagna and G. S. Hanan, *Chem. - Eur. J.*, 2017, **23**, 16497–16504.
- 45 J. Delasoie, A. Pavic, N. Voutier, S. Vojnovic, A. Crochet, J. Nikodinovic-Runic and F. Zobi, *Eur. J. Med. Chem.*, 2020, **204**, 112583.
- 46 J. Delasoie, P. Schiel, S. Vojnovic, J. Nikodinovic-Runic and F. Zobi, *Pharmaceutics*, 2020, **12**, 480.
- 47 G. Santoro, T. Zlateva, A. Ruggi, L. Quaroni and F. Zobi, *Dalton Trans.*, 2015, **44**, 6999–7008.
- 48 J. Rossier, D. Hauser, E. Kottelat, B. Rothen-Rutishauser and F. Zobi, *Dalton Trans.*, 2017, **46**, 2159–2164.
- 49 S. Nasiri Sovari and F. Zobi, *Chemistry*, 2020, **2**, 418–452.
- 50 S. N. Sovari, S. Vojnovic, S. S. Bogojevic, A. Crochet, A. Pavic, J. Nikodinovic-Runic and F. Zobi, *Eur. J. Med. Chem.*, 2020, **205**, 112533.
- 51 J. Delasoie, N. Radakovic, A. Pavic and F. Zobi, *Appl. Sci.*, 2020, **10**, 7380.
- 52 G. Santoro, R. Beltrami, E. Kottelat, O. Blacque, A. Y. Bogdanova and F. Zobi, *Dalton Trans.*, 2016, **45**, 1504–1513.
- 53 L. Prieto, J. Rossier, K. Derszniak, J. Dybas, R. M. Oetterli, E. Kottelat, S. Chlopicki, F. Zelder and F. Zobi, *Chem. Commun.*, 2017, **53**, 6840–6843.
- 54 H. B. Suliman, F. Zobi and C. A. Piantadosi, *Antioxid. Redox Signaling*, 2016, **24**, 345–360.
- 55 F. Zobi, A. Degonda, M. C. Schaub and A. Y. Bogdanova, *Inorg. Chem.*, 2010, **49**, 7313–7322.
- 56 F. Zobi, *Inorg. Chem.*, 2009, **48**, 10845–10855.
- 57 F. Zobi and O. Blacque, *Dalton Trans.*, 2011, **40**, 4994–5001.
- 58 F. Zobi, *Inorg. Chem.*, 2010, **49**, 10370–10377.
- 59 S. P. Schmidt, W. C. Trogler, F. Basolo, M. A. Urbancic and J. R. Shapley, *Inorg. Synth.*, 1990, 160–165, DOI: 10.1002/9780470132593.ch42.
- 60 R. Alberto, A. Egli, U. Abram, K. Hegetschweiler, V. Gramlich and P. A. Schubiger, *Dalton Trans.*, 1994, 2815–2820, DOI: 10.1039/DT9940002815.
- 61 U. Abram, R. Hübener, R. Alberto and R. Schibli, *Z. Anorg. Allg. Chem.*, 1996, **622**, 813–818.
- 62 J. D. Chai and M. Head-Gordon, *Phys. Chem. Chem. Phys.*, 2008, **10**, 6615–6620.
- 63 J. D. Chai and M. Head-Gordon, *J. Chem. Phys.*, 2008, **128**, 084106.
- 64 S. Grimme, *J. Comput. Chem.*, 2006, **27**, 1787–1799.
- 65 A. D. Becke, *J. Chem. Phys.*, 1997, **107**, 8554–8560.
- 66 Q. Wu and W. Yang, *J. Chem. Phys.*, 2002, **116**, 515–524.
- 67 D. Andrae, U. Häußermann, M. Dolg, H. Stoll and H. Preuß, *Theor. Chim. Acta*, 1990, **77**, 123–141.

